Translational-Omics in Aortic Stenosis (TOmAS) Biobank
Cardiovascular Diseases | Aortic Valve StenosisThe objective of the TOmAS Biobank is the conservation of biological material (plasma, saliva, and tissue explanted during surgery), genetic material (DNA, RNA, etc.), and clinical data ("material/data") collected from patients with cardiovascular diseases (CVD) as well as from control participants, in order to allow future studies evaluating novel proteomic, transcriptomic and epigenomic markers (as well as other emerging -omic technologies) for CVD (i.e. aortic stenosis, cardiomyopathy, myorcardial infarction, etc). The study of physiological and genetic factors will allow for the discovery of new genomic and other -omic (including proteomic, transcriptomic and epigenomic) biomarkers associated with CVD which will lead to an improved understanding of the underlying biology of CVD and may provide future insights into the prevention and treatment of this type of disease.
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
19 and up
Critères de participation
Inclusion Criteria:
* CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection.
* Undergoing cardiac surgery for non-aortic valve pathology
Exclusion Criteria:
* Individuals with Congenital heart disease will be excluded
Lieu de l'étude
Montreal General Hospital
Montreal General HospitalMontréal, Quebec
Canada
Contactez l'équipe d'étude
Royal Victoria Hospital
Royal Victoria HospitalMontréal, Quebec
Canada
Contactez l'équipe d'étude
- Étude parrainée par
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT05930899